A U.S. jury found Japan-based Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza via an anticompetitive scheme. japantimes.co.jp/business/2026… #business #companies #us #medicine #takeda #pharmaceuticals #health

To reduce its reliance on Enhertu ahead of the cancer treatment's patent expiry, Daiichi Sankyo is betting on a new wave of antibody-drug conjugates to expand its oncology business. japantimes.co.jp/business/2026… #business #companies #daiichisankyo #health #pharmaceuticals #medicine #patents